NOT
FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN,
INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH
JURISDICTION.
FOR
IMMEDIATE RELEASE
10 OCTOBER
2024
Oxford Nanopore Technologies plc ("Oxford Nanopore" or "the
Company")
New
issue in connection with Oxford Nanopore's Long Term Incentive
Plan
Oxford Nanopore announces that it
intends to issue 12,500,789 ordinary shares of £0.0001 each
("New Ordinary
Shares") to satisfy the release of awards under the
Oxford Nanopore Technologies Limited Long-Term Incentive Plan 2021
("Founder
LTIP"), conditional only upon Admission (as defined
below). The New Ordinary Shares will rank pari passu
with existing ordinary shares in issue.
Applications have been made to the
Financial Conduct Authority and London Stock Exchange for the New
Ordinary Shares to be admitted to the Equity shares (transition)
category of the Official List of the Financial Conduct Authority
and to trading on the main market for
listed securities of the London Stock Exchange ("Admission").
Admission is expected to occur at
8.00 a.m. on 14 October 2024.
For further information, please
contact:
Oxford Nanopore Technologies plc
Investors:
ir@nanoporetech.com
Media:
media@nanoporetech.com
Teneo (communications adviser
to the
Company)
Tom Murray, Olivia Peters
+44 (0) 20 7353 4200
OxfordNanoporeTechnologies@teneo.com
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies' goal is to bring the widest
benefits to society through enabling the analysis of anything, by
anyone, anywhere. The company has developed a new generation of
nanopore-based sensing technology for real-time, high-performance,
accessible and scalable analysis of DNA and RNA. The technology is
used in more than 120 countries to understand the biology of humans
and diseases such as cancer, plants, animals, bacteria, viruses and
whole environments. Oxford Nanopore Technologies products are
intended for molecular biology applications and are not intended
for diagnostic purposes.
www.nanoporetech.com
Forward-looking statements
This announcement contains certain forward-looking statements.
For example, statements regarding expected revenue growth and
profit margins are forward-looking statements. Phrases such as
"aim", "plan", "expect", "intend", "anticipate", "believe",
"estimate", "target", and similar expressions of a future or
forward-looking nature should also be considered forward-looking
statements. Forward-looking statements address our expected future
business and financial performance and financial condition, and by
definition address matters that are, to different degrees,
uncertain. Our results could be affected by macroeconomic
conditions, the COVID-19 pandemic, delays in our receipt of
components or our delivery of products to our customers,
suspensions of large projects and/or acceleration of large products
or accelerated adoption of pathogen surveillance. These or other
uncertainties may cause our actual future results to be materially
different than those expressed in our forward-looking
statements.